SILLAJEN RCC
22 Dec 2020
Trial Summary
This is a phase 1b open-label, multi-centre, dose escalation study of Pexa-Vec (Thyidine Kinase- deactivated vaccinia virus plus GM-CSF) in combination with REGN2810 (anti-PD-1) in patients with metastatic or unresectable renal cell carcinoma (RCC).
Acronym:
JX594-REN026
ACTRN/NCT /ethics:
NCT03294083
Scientific title:
A study of recombinant vaccinia virus in combination with REGN2810 for renal cell carcinoma
Sponsor / Cooperative group:
SillaJen, Inc.
Trial & Patient Characteristics
| Cancer Type | Kidney |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Renal Cell Carcinoma |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2018-06-07 |
| Anticipated End Date | 2020-09-01 |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | - |
| Recruitment Status | Recruiting |